Web Exclusives
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS)—liposarcoma and leiomyosarcoma—that cannot be removed by surgery (unresectable) or is advanced (metastatic). Read More ›
The US Food and Drug Administration (FDA) granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non–small-cell lung cancer (NSCLC) whose disease has progressed after other treatments, and with tumors that express a protein called PD-L1. Read More ›
On September 30, 2015, the US Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma. Read More ›
The National Prescription Drug Take-Back addresses a vital public safety and public health issue. Many patients are not aware that the medicines in their cabinets are highly susceptible to diversion, misuse, and abuse. Read More ›
Adherence to certain strategies can aid pharmacists in successful navigation of our increasingly collaborative healthcare landscape. Read More ›
At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, presented some clinical pearls that can guide the management of dermatologic toxicities. Read More ›
Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options. Read More ›
Most of the illnesses that are encountered in medicine are incurable. Diabetes and heart disease are 2 of the common, chronic, and incurable health conditions that require diligent monitoring. Read More ›
The past decade has given us several breakthrough treatment options for a complex and serious malignancy, multiple myeloma (MM). Read More ›
Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers. Read More ›